ACatechol has received an NSF COVID grant to develop a germicidal coating technology that is effective against microbes (including COVID-19 and secondary infections resulting from COVID-19 treatments) long after application.
Scientists showed that ACatechol’s self-disinfecting surface technology that can provide an additional and effective tool to mitigate the currently existing infectious diseases and can prevent upcoming epidemics/pandemics. The new technology showed up to 100,000,000 times higher surface antimicro
ACatechol’s wet bonding project has received NIH funding to replace/aid suture to avoid painful and catastrophic revision surgery such as tendon-to-bone repair.
ACatechol's team includes scientists and business advisors. The company aims to develop products and technologies that improve surface treatments across a wide variety of industries.
ACatechol develops surface engineering solutions, including anti-pathogenic, anti-bio-fouling, and wet bonding technologies, for medical, dental, and other industries. Its technologies are patented.
